Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial

BACKGROUND: Hematologic malignancy (HM) patients receiving immunosuppressive cancer therapy (ICT) are at increased risk of herpes zoster (HZ). Currently, no HZ vaccine is indicated for immunocompromised patients. The HZ subunit vaccine candidate (HZ/su), containing recombinant varicella zoster virus...

Descripción completa

Detalles Bibliográficos
Autor principal: Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631126/
http://dx.doi.org/10.1093/ofid/ofx163.1040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631126/
http://dx.doi.org/10.1093/ofid/ofx163.1040

Ejemplares similares